Massachusetts General Hospital Mass General 2 — Boston, Massachusetts

Massachusetts General Hospital Mass General 2 is a clinical research site located in Boston, Massachusetts, United States 02114.

Crixeo Health Trust Score: 70/100 (FAIR). This profile has not yet been claimed by the site owner.

Massachusetts General Hospital Mass General 2 has participated in 5 clinical trials.

Therapeutic areas: Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma, Unspecified Adult Solid Tumor, Protocol Specific.

Sponsors: Pfizer, Novartis Pharmaceuticals, Array Biopharma, now a wholly owned subsidiary of Pfizer.

Sponsor Feasibility Report

Trust Score: 70/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Massachusetts General Hospital Mass General 2?

Massachusetts General Hospital Mass General 2 has a Crixeo Trust Score of 70/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Massachusetts General Hospital Mass General 2 conducted?

Massachusetts General Hospital Mass General 2 has 5 clinical trials on record. Their work covers Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma, Unspecified Adult Solid Tumor, Protocol Specific.

Is Massachusetts General Hospital Mass General 2 accredited by Crixeo Health?

Yes — Massachusetts General Hospital Mass General 2 holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Massachusetts General Hospital Mass General 2?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.